Piracetam Is Useful in the Treatment of Children with Sickle Cell Disease

Acta Haematologica

Volumn 96, Issue 4, 1996, Pages 221-226

  El Hazmi, Mohsen A F ^a   Warsy, A S ^b   Al Fawaz, I ^a   Opawoye, A D ^c   Abu Taleb, H ^d   Howsawi, Z ^e   Mohamed, A A ^f   Afy, A W ^g   Refai, S ⁿ   Sugathan, P S ^h   Rab, A Shamsel ⁱ   Ahmed, H B M ^j   Abulaban, M ^k   Abdulkade, A M ^l   Farid, M ^m  

^a Lexington Veterans Affairs Health Care System   (United States)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c Faifa General Hospital   (United States)

^d Madina Al Munawarah ^*  (United States)

^e Obstetrics Paediatrics Hospital   (United States)

^f KING FAHAD HOSPITAL   (Saudi Arabia)

^g Samta General Hospital ^*  (United States)

^h Samta General Hospital   (United States)

ⁱ Sabia General Hospital   (United States)

^j Qunfuda General Hospital   (United States)

^k Khaiber General Hospital   (United States)

^l Qelwa General Hospital   (United States)

^m Shamesi Hospital   (United States)

ⁿ SECURITY FORCES HOSPITAL   (Saudi Arabia)

more..

Author keywords

2 Oxo 1 pyrrolidine acetamide; Hemoglobin S beta; deg; thalassaemia; Piracetam; Sickle cell anaemia; Sickle cell disease

Indexed keywords

PIRACETAM;

AGE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PRIORITY JOURNAL; SAUDI ARABIA; SICKLE CELL ANEMIA; SICKLE CELL CRISIS;

ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; NEUROPROTECTIVE AGENTS; PIRACETAM; SEVERITY OF ILLNESS INDEX;

EID: 10244260461     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203788     Document Type: Article

References (23)

1. Powars DR: Natural history of sickle cell disease in the first ten years. Semin Hematol 1975; 12:267-285.
2. Diggs LW: Sickle cell crises. Am J Clin Pathol 1965;44:1-19.
3. Ohene-Frempong K: Stroke in sickle cell disease. Demographic, clinical and therapeutic considerations. Semin Hematol 1991;28:213-219.
4. Rodgers GP: Recent approaches to the treatment of sickle cell anemia. JAMA Middle East 1991:53-57.
5. Schechter AN, Noguchi CT, Rodger GP: Sickle cell anemia; in Stamatoyannopoulos G, Nien-huis AW, Leder P, Majcrus PW (eds): The Molecular Basis of Blood Diseases. Philadelphia, Saunders, 1987, pp 179-218.
6. Warsy AS, El-Hazmi MAF: Molecular therapy of sickle cell anaemia: The state of art. Saudi Med J 1985;6:257-263.
7. Targino de Araujo J, Nero GS: Piracetam and acetamide in sickle cell disease. Lancet 1977;2: 411.
8. Skondia V: Prophylaxis of sickle cell vaso-occlusive crises with piracetam. International Symposium on Nootropic Drugs, Mexico, 21-22 May 1981. Brussel, Union Chimique Beige, 1981.
9. Nalbandian RM, Henry RL: Desickling mechanisms of piracetam. Blood 1979;54(suppl): 56a.
10. Mikati MA, Solh HM, Deryan DE: A preliminary report on piracetam in sickle cell anemia: A double-blind crossover clinical trial and effects on erythrocyte survival. King Faisal Spec HospMedJ 1983;3:233-236.
11. Costa FF, Zago MA, Bottura C: Effects of piracetam and iodoacetamide on erythrocyte sickling. Lancet 1979;2: 1302.
12. Franklin IM: Piracetam in sickle cell disease. Lancet 1980;1:767.
13. Bick RL, Skondia V: Piracetam: Results of a preliminary in vivo trial as a platelet suppressant. Blood 1979;54(suppl):234a.
14. Gini EK. Sonnet J: Use of piracetam improves sickle cell deformability in vivo. J Clin Pathol 1987;40:99-102.
15. Bick RL, Skondia V, Nix K: Prophylaxis of sickle cell vaso-occlusive crises with oral piracetam. Blood 1981;58/5(suppl):56a.
16. El-Hazmi MAF, Warsy AS, Al-Momen AK, Harakati M: Hydroxyurea for the treatment of sickle cell disease. Acta Haematol 1992;88: 170-174.
17. Dacie JV, Lewis LS: Practical Haematology, ed 5. Edinburgh, Churchill Livingstone, 1975, p42.
18. Kits for Hb F distribution from Boehringer-Mannheim GmbH Diagnostic (Test-Combina-tion Fetal Hemoglobin. Cat. No. 124249). Mannheim, 1983.
19. Marengo-Rowe AJ: Rapid electrophoresis and quantitation of haemoglobins on cellulose acetate. J Clin Pathol 1965;18:790-792.
20. Robinson AR, Robson M, Harrison AP, Zeulz-er WW: A new technique for differentiation of haemoglobin. J Lab Clin Med 1957;50:745-752.
21. Bctke K, Marti HR, Schlicht I: Estimation of small percentage of foetal haemoglobin. Nature 1959;184:1877-1878.
22. El-Hazmi MAF, Al-Fawaz I, Warsy AS: Red cell deformability and the effect of piracetam in sickle cell disease (abstract). Paediatric Symposium. Riyadh, King Khalid University Hospital, 1992.
23. Charache S, Terrin ML. Moore RD. Dower GJ, Barton FB, Eckert SV, McMahan RP, Bonds DR, investigators of the Multicentcr Study of Hydroxyurea in Sickle Cell Anaemia: Effect of hydroxyurea on the frequency of painful crises in sickle cell anaemia. N Engl J Med 1995;332: 1317-1322